GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.51 Billion KRW | -4.53% |
| 2022 | 41.39 Billion KRW | -6.01% |
| 2021 | 44.04 Billion KRW | 15.71% |
| 2020 | 38.06 Billion KRW | 40.49% |
| 2019 | 27.09 Billion KRW | 36.24% |
| 2018 | 19.88 Billion KRW | 118.67% |
| 2017 | 9.09 Billion KRW | -69.49% |
| 2016 | 29.8 Billion KRW | 261.22% |
| 2015 | 8.25 Billion KRW | 36.74% |
| 2014 | 6.03 Billion KRW | -25.58% |
| 2013 | 8.1 Billion KRW | -38.66% |
| 2012 | 13.22 Billion KRW | 98.26% |
| 2011 | 6.66 Billion KRW | -16.81% |
| 2010 | 8.01 Billion KRW | -58.48% |
| 2009 | 19.3 Billion KRW | 115.61% |
| 2008 | 8.95 Billion KRW | 11.99% |
| 2007 | 7.99 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 38.34 Billion KRW | -2.98% |
| 2024 Q2 | 45.16 Billion KRW | 17.81% |
| 2023 Q1 | 42.66 Billion KRW | 3.07% |
| 2023 Q2 | 34.34 Billion KRW | -19.51% |
| 2023 FY | 39.51 Billion KRW | -4.53% |
| 2023 Q3 | 33.05 Billion KRW | -3.76% |
| 2023 Q4 | 39.51 Billion KRW | 19.56% |
| 2022 Q1 | 42.36 Billion KRW | -3.8% |
| 2022 Q3 | 44.51 Billion KRW | -3.14% |
| 2022 Q4 | 41.39 Billion KRW | -7.0% |
| 2022 FY | 41.39 Billion KRW | -6.01% |
| 2022 Q2 | 45.95 Billion KRW | 8.47% |
| 2021 FY | 44.04 Billion KRW | 15.71% |
| 2021 Q1 | 34.05 Billion KRW | -10.53% |
| 2021 Q2 | 38.35 Billion KRW | 12.63% |
| 2021 Q3 | 48.16 Billion KRW | 25.56% |
| 2021 Q4 | 44.04 Billion KRW | -8.55% |
| 2020 FY | 38.06 Billion KRW | 40.49% |
| 2020 Q2 | 16.92 Billion KRW | 3.61% |
| 2020 Q3 | 11.52 Billion KRW | -31.94% |
| 2020 Q4 | 38.06 Billion KRW | 230.38% |
| 2020 Q1 | 16.33 Billion KRW | -39.7% |
| 2019 Q1 | 25.29 Billion KRW | 27.19% |
| 2019 FY | 27.09 Billion KRW | 36.24% |
| 2019 Q3 | 27.4 Billion KRW | -3.52% |
| 2019 Q2 | 28.4 Billion KRW | 12.31% |
| 2019 Q4 | 27.09 Billion KRW | -1.15% |
| 2018 Q3 | 18.01 Billion KRW | -1.39% |
| 2018 Q4 | 19.88 Billion KRW | 10.41% |
| 2018 Q2 | 18.26 Billion KRW | 155.67% |
| 2018 Q1 | 7.14 Billion KRW | -21.44% |
| 2018 FY | 19.88 Billion KRW | 118.67% |
| 2017 FY | 9.09 Billion KRW | -69.49% |
| 2017 Q4 | 9.09 Billion KRW | -69.61% |
| 2017 Q3 | 29.92 Billion KRW | -0.33% |
| 2017 Q2 | 30.02 Billion KRW | 0.84% |
| 2017 Q1 | 29.77 Billion KRW | -0.12% |
| 2016 Q2 | 32.5 Billion KRW | 194.59% |
| 2016 FY | 29.8 Billion KRW | 261.22% |
| 2016 Q4 | 29.8 Billion KRW | -2.39% |
| 2016 Q3 | 30.53 Billion KRW | -6.05% |
| 2016 Q1 | 11.03 Billion KRW | 33.71% |
| 2015 FY | 8.25 Billion KRW | 36.74% |
| 2015 Q4 | 8.25 Billion KRW | 19.32% |
| 2015 Q3 | 6.91 Billion KRW | -9.09% |
| 2015 Q2 | 7.6 Billion KRW | 40.08% |
| 2015 Q1 | 5.43 Billion KRW | -10.01% |
| 2014 Q3 | 7.82 Billion KRW | 5.22% |
| 2014 Q2 | 7.43 Billion KRW | 10.18% |
| 2014 Q1 | 6.74 Billion KRW | -16.8% |
| 2014 FY | 6.03 Billion KRW | -25.58% |
| 2014 Q4 | 6.03 Billion KRW | -22.84% |
| 2013 FY | 8.1 Billion KRW | -38.66% |
| 2013 Q4 | 8.1 Billion KRW | 35.44% |
| 2013 Q3 | 5.98 Billion KRW | 7.23% |
| 2013 Q2 | 5.58 Billion KRW | -26.12% |
| 2013 Q1 | 7.55 Billion KRW | -42.83% |
| 2012 Q4 | 13.22 Billion KRW | 0.0% |
| 2012 FY | 13.22 Billion KRW | 98.26% |
| 2012 Q1 | 12.2 Billion KRW | 0.0% |
| 2011 FY | 6.66 Billion KRW | -16.81% |
| 2011 Q3 | 5.24 Billion KRW | -11.15% |
| 2011 Q2 | 5.9 Billion KRW | -8.45% |
| 2011 Q1 | 6.44 Billion KRW | 0.0% |
| 2010 Q1 | 21.78 Billion KRW | 0.0% |
| 2010 FY | 8.01 Billion KRW | -58.48% |
| 2010 Q3 | 6.88 Billion KRW | -66.13% |
| 2010 Q2 | 20.34 Billion KRW | -6.63% |
| 2009 FY | 19.3 Billion KRW | 115.61% |
| 2009 Q3 | 17.42 Billion KRW | 115.27% |
| 2009 Q2 | 8.09 Billion KRW | -24.26% |
| 2009 Q1 | 10.68 Billion KRW | 19.35% |
| 2008 Q1 | 7.95 Billion KRW | -0.56% |
| 2008 Q2 | 9.05 Billion KRW | 13.96% |
| 2008 Q3 | 8.94 Billion KRW | -1.3% |
| 2008 Q4 | 8.95 Billion KRW | 0.13% |
| 2008 FY | 8.95 Billion KRW | 11.99% |
| 2007 Q2 | 3.97 Billion KRW | -2.99% |
| 2007 FY | 7.99 Billion KRW | 0.0% |
| 2007 Q4 | 7.99 Billion KRW | 96.68% |
| 2007 Q3 | 4.06 Billion KRW | 2.15% |
| 2007 Q1 | 4.1 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ORIENT BIO Inc. | 11.89 Billion KRW | -232.317% |
| Green Cross Holdings Corporation | 1856.16 Billion KRW | 97.871% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | 96.419% |
| Pharmicell Co., Ltd. | 18.79 Billion KRW | -110.268% |
| Green Cross Corporation | 1103.45 Billion KRW | 96.419% |
| Celltrion, Inc. | 2791.73 Billion KRW | 98.584% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 99.364% |
| SK bioscience Co.,Ltd. | 148.58 Billion KRW | 73.403% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | 90.175% |
| Prestige BioPharma Limited | 196.21 Billion KRW | 79.86% |